System and method for magnifying an immune response

• US 20060047436A1
• Filed: 08/25/2004
• Published: 03/02/2006
• Est. Priority Date: 08/25/2004
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Myhrvold, Nathan P., Wood, Lowell L. Jr., Jung, Edward K.Y., Wilson, Richa
• Application Number:
  US10/926,753
• Publication Number:
  US 20060047436A1
• Time in Patent Office: Days
• US Class Current: 702/19
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002

Abstract

The present application relates, in general, to a system and/or method for detection and/or treatment.

Claims

1. A method, comprising:

delivering a treatment to a host wherein the treatment is associated with modulating a predicted pattern of progression of one or more antigenic determinants.

2. The method of claim 1, wherein the treatment further comprises:

delivering at least a part of one or more of a macrophage, a lymphocyte, a T-lymphocyte, a killer T-lymphocyte, an immune response modulator, a helper T-lymphocyte, an antigen receptor, an antigen presenting cell, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a cluster differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

3. The method of claim 1, wherein the treatment further comprises:

delivering one or more modulators of at least a part of at least one of a macrophage, a lymphocyte, a T-lymphocyte, a killer T-lymphocyte, an immune response modulator, a helper T-lymphocyte, an antigen receptor, an antigen presenting cell, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a cluster differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

4. The method of claim 1, wherein the treatment further comprises:

delivering at least a part of a B-lymphocyte.

5. The method of claim 1, wherein the treatment further comprises:

delivering at least one of a modulator of at least a part of a B-lymphocyte.

6. The method of claim 1, wherein the treatment further comprises:

delivering at least a part of one or more of an antibody, a recombinant antibody, a genetically engineered antibody, a chimeric antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, a diabody, a chimeric antibody, a humanized antibody, a human antibody, a heteroantibody, a monoclonal antibody, a polyclonal antibody, or an antibody fragment.

7. The method of claim 1, wherein the treatment further comprises:

delivering one or more modulators of at least a part of at least one of an antibody, a recombinant antibody, a genetically engineered antibody, a chimeric antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, a diabody, a chimeric antibody, a humanized antibody, a human antibody, a heteroantibody, a monoclonal antibody, a polyclonal antibody, or an antibody fragment.

8. The method of claim 1, wherein the delivering a treatment to a host further comprises:

delivering the treatment by at least one of a sub-cutaneous route, a nasal route, an intranasal route, an intramuscular route, an intravenous route, an intraarterial route, an intrathecal route, an intracapsular route, an intraorbital route, an intracardiac route, a transdermal route, an intradermal route, an intraperitoneal route, a transtracheal route, a subcuticular route, an intraarticular route, a subcapsular route, a subarachnoidal route, an intraspinal route, an epidural route, an intrasternal route, an infusion route, a topical route, a sublingual route, or an enteric route.

9. A system comprising, comprising:

circuitry for suggesting delivery of a treatment to a host wherein the treatment is associated with modulating a predicted pattern of progression of one or more antigenic determinants.

10. The system of claim 9, wherein the treatment further comprises:

delivering at least a part of one or more of a macrophage, a lymphocyte, a T-lymphocyte, a killer T-lymphocyte, an immune response modulator, a helper T-lymphocyte, an antigen receptor, an antigen presenting cell, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a cluster differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

11. The system of claim 9, wherein the treatment further comprises:

delivering one or more modulators of at least a part of at least one of a macrophage, a lymphocyte, a T-lymphocyte, a killer T-lymphocyte, an immune response modulator, a helper T-lymphocyte, an antigen receptor, an antigen presenting cell, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a cluster differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

12. The system of claim 9, wherein the treatment further comprises:

delivering at least a part of a B-lymphocyte.

13. The system of claim 9, wherein the treatment further comprises:

delivering at least one of a modulator of at least a part of a B-lymphocyte.

14. The system of claim 9, wherein the treatment further comprises:

delivering at least a part of one or more of an antibody, a recombinant antibody, a genetically engineered antibody, a chimeric antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, a diabody, a chimeric antibody, a humanized antibody, a human antibody, a heteroantibody, a monoclonal antibody, a polyclonal antibody, or an antibody fragment.

15. The system of claim 9, wherein the treatment further comprises:

delivering one or more modulators of at least a part of at least one of an antibody, a recombinant antibody, a genetically engineered antibody, a chimeric antibody, a monospecific antibody, a bispecific antibody, a multispecific antibody, a diabody, a chimeric antibody, a humanized antibody, a human antibody, a heteroantibody, a monoclonal antibody, a polyclonal antibody, or an antibody fragment.

16. The system of claim 9, wherein the delivering a treatment to a host further comprises:

delivering the treatment by at least one of a sub-cutaneous route, a nasal route, an intranasal route, an intramuscular route, an intravenous route, an intraarterial route, an intrathecal route, an intracapsular route, an intraorbital route, an intracardiac route, a transdermal route, an intradermal route, an intraperitoneal route, a transtracheal route, a subcuticular route, an intraarticular route, a subcapsular route, a subarachnoidal route, an intraspinal route, an epidural route, an intrastemal route, an infusion route, a topical route, a sublingual route, or an enteric route.

17. A system, comprising:

a computer readable medium including, but not limited to, a computer program for use with a computer system and wherein the computer program includes a plurality of instructions including;

one or more instructions for selecting one or more determining elements;

one or more instructions for predicting at least one pattern change in the one or more determining elements;

one or more instructions for associating the at least one pattern change in the one or more determining elements with at least one outcome; and

one or more instructions for designating a course of action associated with the at least one pattern change in the one or more determining elements.

18. The system of claim 17, wherein the computer readable medium further comprises:

one or more instructions for identifying one or more treatments corresponding to the one or more determining elements.

19. The system of claim 17, wherein the computer readable medium further comprises:

one or more instructions for identifying one or more treatments responsive for modulating a host defense mechanism.

20. The system of claim 17, wherein the one or more instructions for designating a course of action further comprises:

one or more instructions for including at least one parameter including a location, number, an antigenicity profile, a type of immune response component, an availability of an antibody, a sequence match with a host, or a sequence match with an agent.

21. The system of claim 17, wherein the at least one outcome further comprises:

an outcome predicting a pattern of change in one or more immune response components.

22. A system, comprising:

circuitry for selecting one or more determining elements;

circuitry for predicting at least one pattern change in the one or more determining elements;

circuitry for associating the at least one pattern change in the one or more determining elements with at least one outcome; and

circuitry for designating a course of action associated with the at least one pattern change in the one or more determining elements.

23. A system, comprising:

means for selecting one or more determining elements;

means for predicting at least one pattern change in the one or more determining elements;

means for associating the at least one pattern change in the one or more determining elements with at least one outcome; and

means for designating a course of action associated with the at least one pattern change in the one or more determining elements.